Merck Reports EC’s Approval of Keytruda for Two New Indications in Gynecologic Cancers
Shots:
- The EC has approved Keytruda with carboplatin & paclitaxel as a 1L treatment of adults with primary advanced or recurrent endometrial carcinoma, eligible for systemic therapy and with CRT for treatment-naïve adults with locally advanced cervical cancer (stage III-IVA)
- Approvals were based on P-III (NRG-GY018) study of Keytruda + CT for endometrial cancer in pMMR & dMMR cohorts, P-III (KEYNOTE-A18) study of Keytruda + CRT for cervical cancer and positive opinions from CHMP
- NRG-GY018, in Jun 2024, study showed a reduction in the disease progression or death risk by 70% in dMMR cohort and 40% in pMMR cohort. KEYNOTE-A18, in Jan 2024, trial depicted improved OS & PFS, with a reduction in the disease progression or death risk by 41%
Ref: Merck | Image: Merck
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
